Generic Medicine Info
May be taken with or without food.
Obstruction of bowel, significant bladder obstruction, myasthenia gravis, intestinal atony, severe ulcerative colitis, toxic megacolon, uncontrolled angle-closure glaucoma, tachyarrhythmias. Moderate to severe hepatic impairment. Pregnancy and lactation.
Special Precautions
Patient w/ autonomic neuropathy and those who are susceptible to angle-closure glaucoma. May exacerbate severe CHF (NYHA IV), cardiac arrhythmia, tachycardia, hiatus hernia w/ reflux oesophagitis, prostatic hyperplasia. Patients receiving potent flavin-containing monooxygenase (FMO) inhibitors (e.g. methimazole) in combination w/ potent CYP 3A4/5 inhibitors. Hepatic or renal impairment. Patient Counselling This drug may cause drowsiness and blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor liver enzyme values in long-term therapy.
Adverse Reactions
Hypotension, drowsiness, headache, dizziness, tremor, dysgeusia, blurred vision, palpitation, dry mouth, constipation, abdominal pain, dyspepsia, nausea, vomiting, flushing, urinary retention, fatigue.
Drug Interactions
Reduced BP when used w/ isoniazid. Drowsiness may be enhanced by drugs w/ CNS depressant properties. May decrease the effect of prokinetics (e.g. metoclopramide). Decreased effect when used w/ cholinergic drugs. Increased effect when used w/ TCAs, tranquilisers, anticholinergics, amantadine, neuroleptics and β-adrenoceptor agonists.
ATC Classification
G04BD06 - propiverine ; Belongs to the class of urinary antispasmodics.
Disclaimer: This information is independently developed by CIMS based on propiverine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in